Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyverna Therapeutics is redefining autoimmune care with CD19-targeted CAR T cells, yet its SEC disclosures weave together trial endpoints, collaboration milestones, and dilution details that can bury critical signals. If you鈥檝e ever searched dozens of PDFs for one R&D expense line or an FDA hold notice, you already know the pain.
Stock Titan removes that friction. Our AI reads every submission the second it hits EDGAR, then delivers Kyverna Therapeutics SEC filings explained simply. Drill into a Kyverna Therapeutics annual report 10-K simplified to see cash runway and pipeline updates, or open a Kyverna Therapeutics quarterly earnings report 10-Q filing for side-by-side trend analysis. Need real-time insider sentiment? We surface Kyverna Therapeutics insider trading Form 4 transactions and flag any Kyverna Therapeutics Form 4 insider transactions real-time. Material news is never missed鈥攅ach Kyverna Therapeutics 8-K material events explained highlights clinical trial pauses, partnership payments, or equity offerings in plain language.
Professionals use the platform to:
- Track R&D spend vs. cash on hand through our Kyverna Therapeutics earnings report filing analysis.
- Monitor management incentives via Kyverna Therapeutics proxy statement executive compensation.
- Spot buying or selling trends with Kyverna Therapeutics executive stock transactions Form 4.
- Save hours by understanding Kyverna Therapeutics SEC documents with AI instead of wading through 250-page reports.
Whether you鈥檙e preparing a valuation model or checking compliance, Stock Titan鈥檚 AI-powered summaries, expert context, and real-time alerts make complex biotech filings effortless.
Kyverna Therapeutics is a clinical-stage biopharma developing CAR T cell therapies for autoimmune diseases. For the quarter ended June 30, 2025, the company reported a net loss of $42.1 million and a six-month net loss of $86.7 million, with net loss per share of $0.97 for the quarter. Accumulated deficit stood at $350.2 million. As of June 30, 2025, Kyverna held $53.4 million in cash and $158.2 million in available-for-sale marketable securities, totaling $211.7 million of liquidity; management estimates this funding is sufficient for at least the next 12 months and into 2027 under the current plan.
Operationally, Kyverna completed enrollment in its registrational Phase 2 KYSA-8 study for stiff person syndrome in Q2 2025 and expects data in the first half of 2026. The KYSA-6 trial in myasthenia gravis has completed enrollment, interim data are planned for Q4 2025, and the trial is being expanded to include a Phase 3 portion expected to begin enrollment by year-end 2025. The company also noted FDA alignment on CMC readiness and plans to support a BLA filing for SPS in the first half of 2026. The company faces securities class and derivative litigation; no loss accruals were recorded as of June 30, 2025.
Kyverna Therapeutics, Inc. furnished a press release providing a business update and reporting financial results for the quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1.
The company notes this information is furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into registration statements. Kyverna's common stock trades on Nasdaq under the symbol KYTX, and the registrant is identified as an emerging growth company.
Kyverna Therapeutics (ticker KYTX) filed a Form 4 disclosing that its Chief Financial Officer, Marc Grasso, received an equity award on 30 June 2025. The transaction involves a single grant of 450,000 stock options with an exercise price of $3.07 and an expiration date of 30 June 2035.
The vesting schedule follows a standard four-year pattern: 25 % (112,500 options) vests on 30 June 2026, after which 1鈦�48 of the total options (9,375 shares) vest monthly for the next 36 months, contingent on Grasso鈥檚 continued employment. The filing shows direct ownership (D) of the derivative security, and no other changes to common-stock holdings were reported.
This award aligns the CFO鈥檚 incentives with long-term shareholder value creation and signals a retention commitment by the company. If fully exercised, the award would add up to 450,000 new common shares to the float, a modest potential dilution given Kyverna鈥檚 recent post-IPO share count of roughly 55-60 million (based on prior filings). No cash transactions were reported, and the filing contains no earnings or operational updates.
FAQ
What is the current stock price of Kyverna Therapeutics (KYTX)?
What is the market cap of Kyverna Therapeutics (KYTX)?
